Dr. Alex Weisman, the founder, and principal of Calathea Pharma Ltd.
For the past 25 years, Alex managed R&D and BD activities of Perrigo’s subsidiary “Perrigo API Ltd” (former “ChemAgis”) and was in charge for the development chain (Products selection and portfolio management, IP, Synthetic and Analytical development, Pilot and Regulatory affairs, etc.). Prior to this, Alex completed a postdoctoral fellowship in the Organic chemistry department of Weitzman Institute of Science (Israel). Alex holds a Ph.D. in Biochemistry.
Yoav Grinberg, the founder, and principal of Calathea Pharma Ltd.
In his last position, Yoav managed Perrigo subsidiary “Perrigo API (ChemAgis)” and pervious to this he managed industrial companies in Israel and UK and was Director in many companies in the US, India and Europe.
Yoav holds an MBA in Marketing and Finance from Tel Aviv University.